Abstract:

Liver cancer is one of the most common malignant tumors worldwide. Due to lack of specific clinical manifestations during the early stage, most patients with liver cancer are diagnosed at middle and late stage, missing the opportunity of radical surgery. Interventional therapy, sequential targeted therapy, immunotherapy and other comprehensive therapies are mainly adopted for middle and late stage liver cancer. It is of significance to evaluate clinical efficacy on a regular basis, which can not only reflect the efficacy of preliminary treatment, but also provide guidance for subsequent treatment. Liver cancer belongs to solid tumor, and the evaluation systems of solid tumor response have gradually developed from WHO criteria, response evaluation criteria in solid tumours (RECIST) to modified RECIST (mRECIST) which is suitable for evaluating targeted therapy. With the development of tumor treatment regimen, multiple problems have been identified in the use of traditional evaluation system, which fail to comprehensively and accurately evaluate clinical efficacy of tumor treatment. Therefore, it is urgent to employ existing advanced technologies to establish a more comprehensive and accurate evaluation system. In this article, traditional evaluation systems of solid tumor response inlcuding liver cancer were reviewed.

Key words: Liver neoplasms, Solid tumors, WHO criteria, RECIST criteria, Evaluation of efficacy